Previous close | 130.90 |
Open | 140.00 |
Bid | 130.45 x 100 |
Ask | 130.65 x 100 |
Day's range | 130.05 - 142.79 |
52-week range | 55.25 - 159.89 |
Volume | |
Avg. volume | 854,572 |
Market cap | 12.345B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
CAMBRIDGE, Mass., May 01, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2024.
CAMBRIDGE, Mass., April 30, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 30, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in April 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
CAMBRIDGE, Mass., April 24, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2024 financial results.